首页> 外文期刊>The Journal of Urology >Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
【24h】

Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.

机译:由microRNA表达谱定义的膀胱尿路上皮癌的分期,等级和行为。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We identified miRNA expression profiles in urothelial carcinoma that are associated with grade, stage, and recurrence-free and disease specific survival. MATERIALS AND METHODS: The expression of 14 miRNAs was evaluated by quantitative reverse transcriptase-polymerase chain reaction in surgical specimens from 30 patients with low grade, noninvasive (pTa) and 30 with high grade, invasive (pT2-3) urothelial carcinoma. Controls were normal bladder tissue from 5 patients who underwent surgical treatment for benign prostatic hyperplasia. Endogenous controls were RNU-43 and RNU-48. miRNA profiles were compared and Kaplan-Meier curves were constructed to analyze disease-free and disease specific survival. RESULTS: miR-100 was under expressed in 100% of low grade pTa specimens (p <0.001) and miR-10a was over expressed in 73.3% (p <0.001). miR-21 and miR-205 were over expressed in high grade pT2-3 disease (p = 0.02 and <0.001, respectively). The other miRNAs were present at levels similar to those of normal bladder tissue or under expressed in each tumor group. miR-21 over expression (greater than 1.08) was related to shorter disease-free survival in patients with low grade pTa urothelial carcinoma. Higher miR-10a levels (greater than 2.30) were associated with shorter disease-free and disease specific survival in patients with high grade pT2-3 urothelial carcinoma. CONCLUSIONS: Four miRNAs were differentially expressed in the 2 urothelial carcinoma groups. miR-100 and miR-10a showed under expression and over expression, respectively, in low grade pTa tumors. miR-21 and miR-205 were over expressed in pT2-3 disease. In addition, miR-10a and miR-21 over expression was associated with shorter disease-free and disease specific survival. miRNAs could be incorporated into the urothelial carcinoma molecular pathway. These miRNAs could also serve as new diagnostic or prognostic markers and new target drugs.
机译:目的:我们确定了尿路上皮癌中的miRNA表达谱,与年龄,分期,无复发和疾病特异性生存有关。材料与方法:通过定量逆转录酶聚合酶链反应评估了30例低度,非浸润性(pTa)和30例高度,浸润性(pT2-3)尿路上皮癌患者的手术标本中14种miRNA的表达。对照是来自5名接受良性前列腺增生手术治疗的患者的正常膀胱组织。内源性对照是RNU-43和RNU-48。比较了miRNA谱图,并构建了Kaplan-Meier曲线以分析无病生存期和特定疾病生存期。结果:低等级pTa标本中100%的miR-100表达不足(p <0.001),而73.3%的miR-10a过度表达(p <0.001)。 miR-21和miR-205在高度pT2-3疾病中过表达(分别为p = 0.02和<0.001)。其他miRNA的存在水平与正常膀胱组织相似,或在每个肿瘤组中表达不足。 miR-21过表达(大于1.08)与低级pTa尿路上皮癌患者的无病生存期较短有关。较高的miR-10a水平(大于2.30)与高度pT2-3尿路上皮癌患者的无病生存期和疾病特异性生存期有关。结论:在两个尿路上皮癌组中有四个miRNA差异表达。 miR-100和miR-10a在低度pTa肿瘤中分别表达不足和过度表达。 miR-21和miR-205在pT2-3疾病中过表达。另外,miR-10a和miR-21过表达与较短的无病生存期和疾病特异性生存期有关。 miRNA可以整合到尿路上皮癌分子途径中。这些miRNA还可以用作新的诊断或预后标志物以及新的靶标药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号